A clinical trial to study the effects of additional treatments for patients hospitalized and receiving treatment due to COVID -19

INTERVENTION: Intervention1: Remdesivir: local standard of care plus Remdesivir (daily infusion for 10 days) Intervention2: chloroquine or hydroxychloroquine: local standard of care plus chloroquine or hydroxychloroquine (two oral loading doses, then orally twice daily for 10 days) Intervention3: Lopinavir with Ritonavir (orally twice daily for 14 days): Local standard of Care plus Lopinavir with Ritonavir (orally twice daily for 14 days) Intervention4: Lopinavir with Ritonavir (ditto) plus Interferon: Local standard of care plus Lopinavir with Ritonavir ((orally twice daily for 14 days) plus Interferon (daily injection for 6 days). Control Intervention1: Local standard of care: Local standard of care CONDITION: Health Condition 1: B972‐ Coronavirus as the cause of diseases classified elsewhere PRIMARY OUTCOME: All‐cause mortality, subdivided by the severity of disease at the time of randomization, measured using patient records throughout the studyTimepoint: Throughout the study SECONDARY OUTCOME: Measured using patient records: ; 1. Duration of hospital stay (hours) ; 2. Time to first receiving ventilation (or intensive care) (hours)Timepoint: Measured using patient records: ; 1. Duration of hospital stay (hours) ; 2. Time to first receiving ventilation (or intensive care) (hours) INCLUSION CRITERIA: 1. Adults (aged â?Â¥18 years) hospitalized with definite COVID‐19 2. Not already receiving any of the study drugs 3. Without known allergy or contraindications to any of them (in the view of the physician responsible for their care) 4. Without anticipated transfer within 72 h to a non‐study hospital Patients invited to join the study will be those who are admitted to a collaborating hospital; no wider recruitment efforts are expected